Related Experiment Videos
[Thrombosis caused by active rapamycin stents]
R Aoudia-Mentfakh1, F Raoux, J P Collet
1Département de cardiologie médicale, institut de cardiologie, Paris.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|March 23, 2004
Summary
Patients stopping anti-platelet therapy after rapamycin stent placement risk stent thrombosis. Continued dual anti-platelet therapy for 9 months and delaying surgery for 6 months post-stenting are recommended.
Area of Science:
- Cardiology
- Interventional Cardiology
- Vascular Medicine
Background:
- Drug-eluting stents (DES), particularly those with rapamycin coatings, are widely used to prevent restenosis after percutaneous coronary intervention (PCI).
- Anti-platelet therapy is crucial for stent patency, but its interruption, especially before major surgery, poses a significant risk.
- Patient management involves balancing the benefits of revascularization with the risks of stent thrombosis and surgical complications.
Observation:
- A 68-year-old patient experienced recurrent anterior myocardial infarction with cardiogenic shock due to rapamycin stent thrombosis 77 days post-angioplasty.
- Stent thrombosis was precipitated by the cessation of dual anti-platelet therapy due to planned cancer recurrence surgery.
- The patient had a history of diabetes mellitus, a known risk factor for cardiovascular events.
Findings:
- Discontinuation of anti-platelet therapy, even with active stents, significantly increases the risk of stent thrombosis.
- The optimal duration of dual anti-platelet therapy after rapamycin stent implantation appears to be at least 9 months.
- A minimum waiting period of 6 months is advised between rapamycin stent revascularization and non-cardiac surgery.
Implications:
- Continuation of dual anti-platelet therapy for at least 9 months is recommended following rapamycin stent implantation, irrespective of stent type.
- Elective non-cardiac surgery should be postponed for at least 6 months after rapamycin stent procedures.
- In cases where non-cardiac surgery is planned around the time of angioplasty, the use of active stents should be carefully reconsidered, potentially favoring bare-metal stents.